[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352071-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352071-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tumor-associated-protease-activated-anti-cd47-antibody-precisely-maintains-phagocytic-ability-of-macrophages-with-minimal-effect-on-healthy-tissue","Tumor-associated protease-activated anti-CD47 antibody precisely maintains phagocytic ability of macrophages with minimal effect on healthy tissue","","CD47 is highly expressed on many cancer cells and functions as an innate immune checkpoint by engaging SIRPα on macrophages to prevent phagocytosis. Despite the therapeutic use of anti-CD47 antibodies to restore phagocytic capacity, CD47’s widespread presence on normal cells causes serious toxicities, including anemia, thrombocytopenia, and sepsis. A protease-activated, spatial-hindrance antibody design (Pro-αCD47) reduces nonselective binding and enables disease-region activation to improve safety while preserving anti-tumor function.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tumor-associated-protease-activated-anti-cd47-antibody-precisely-maintains-phagocytic-ability-of-macrophages-with-minimal-effect-on-healthy-tissue/352071/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tumor-associated-protease-activated-anti-cd47-antibody-precisely-maintains-phagocytic-ability-of-macrophages-with-minimal-effect-on-healthy-tissue/352071.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"为什么CD47是抗肿瘤治疗的重要靶点？","Question",{"text":63,"@type":64},"CD47在多种癌细胞中高表达，通过与巨噬细胞上的SIRPα结合传递“不要吞噬”的信号，从而帮助肿瘤细胞逃避免疫监视与吞噬作用。","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Pro-αCD47 Ab如何降低抗体治疗的系统性毒性？",{"text":68,"@type":64},"研究使用基于空间位阻的抗体锁定策略，并将其连接到轻链/重链末端，利用MMP-2相关机制在蛋白酶过表达的疾病区域选择性解锁，从而减少对正常组织的非选择性作用。",{"name":70,"@type":61,"acceptedAnswer":71},"Pro-αCD47 Ab的效果如何验证其抗肿瘤能力与安全性？",{"text":72,"@type":64},"体内异种移植研究显示Pro-αCD47 Ab可实现剂量依赖且接近完全的肿瘤抑制，且通过动物体重等指标证明其系统安全性稳定；同时，MMP-2处理后其结合功能可被恢复。","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352071,1790253467,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Chen et al. Journal of Translational Medicine (2026) 24:1060  \n[https://doi.org/10.1186/s12967-026-08293-w](https://doi.org/10.1186/s12967-026-08293-w)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nTumor-associated protease-activated anti- CD47 antibody precisely maintains phagocytic ability of macrophages with minimal effect on healthy tissue  \nYu-Tung Chen1, Zih-Yu Jhuang1, Pin-Jie Li2, Yun-Chi Lu3, Bo-Cheng Huang4,5, Chin-Yuan Chang6, Yu-Cheng Su4,6,7, Chih-Hung Chuang4,8, Tian-Lu Cheng1,4,7, Fang-Ming Chen4,9,10,11, Shih-Yi Lin 12, Hsin-Kai Huang12 and  \nWen-Wei Lin 1,4,13,14,15*  \nAbstract  \n(Background) CD47 is highly expressed on many cancer cells and acts as an innate immune checkpoint. Its binding to signal regulatory protein alpha (SIRPα) on macrophages enables cancer cells to evade phagocytosis. Although anti-CD47 antibody (αCD47 Ab) has been employed to restore phagocytic capacity, the ubiquitous expression of CD47 on normal cells results in significant toxicities during Ab treatment, such as anemia, thrombocytopenia, and sepsis.  \nMethods To mitigate these side effects, we used an autologous hinge region as a spatial-hindrance-based Ab lock and connected it to the N-terminal of the light chain and heavy chain via matrix metalloprotease substrate peptides (i. e., MMP-2) to cover the complementarity-determining regions (CDR) of αCD47 Ab to generate Pro-αCD47 Ab. The Ab lock is selectively removed only in disease regions with overexpressed proteases, thereby reducing the nonselective on-target effect.  \nResults Our results showed that Pro-αCD47 Ab exhibits a 225 . 9-fold weaker binding ability compared to parental αCD47 Ab but fully recovers its binding function following MMP-2 treatment. Significantly, Pro-αCD47 Ab exhibits a 100. 2-fold and 83. 7-fold reduction in binding affinity toward red blood cells and neutrophils, respectively, thereby minimizing the risk of hematological toxicities. Furthermore, in vivo xenograft studies confirmed that Pro-αCD47 Ab achieves dose-dependent and near-complete tumor suppression equivalent to the parental antibody, while maintaining a stable systemic safety profile as evidenced by consistent animal body weight. Besides, it was successfully demonstrated that Pro-αCD47 Ab can be activated by endogenous MMP-2 within clinical tumor specimens, specifically showing promising activation in triple-negative breast cancer (TNBC) samples, thereby restoring its ability to bind CD47 .  \n*Correspondence:  \nWen-Wei Lin [weber06272000@gmail.com](weber06272000@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nChen et al. Journal of Translational Medicine (2026) 24:1060 Page 2 of 12  \nConclusion In summary, we developed a protease-activated Pro-αCD47 Ab that avoids the undesired interactions with normal tissues, thereby add","cbCaikl0JdBRNWgT","https://ap.wps.com/l/cbCaikl0JdBRNWgT","pdf",2359634,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background","[{\"question\":\"为什么CD47是抗肿瘤治疗的重要靶点？\",\"answer\":\"CD47在多种癌细胞中高表达，通过与巨噬细胞上的SIRPα结合传递“不要吞噬”的信号，从而帮助肿瘤细胞逃避免疫监视与吞噬作用。\"},{\"question\":\"Pro-αCD47 Ab如何降低抗体治疗的系统性毒性？\",\"answer\":\"研究使用基于空间位阻的抗体锁定策略，并将其连接到轻链/重链末端，利用MMP-2相关机制在蛋白酶过表达的疾病区域选择性解锁，从而减少对正常组织的非选择性作用。\"},{\"question\":\"Pro-αCD47 Ab的效果如何验证其抗肿瘤能力与安全性？\",\"answer\":\"体内异种移植研究显示Pro-αCD47 Ab可实现剂量依赖且接近完全的肿瘤抑制，且通过动物体重等指标证明其系统安全性稳定；同时，MMP-2处理后其结合功能可被恢复。\"}]","Tumor-associated protease-activated anti-CD47 antibody precisely maintains phagocytic ability of macrophages with minimal effect on healthy tissue | PDF",1790097553,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d891fc080825902cbf9b224dc110bc30.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36791e60a7bef6616047e161607813a1.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cea9e3bd1c34eb1859c6238254bd34f1.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/007d96d5fe8944ea06e88026bca09fb9.webp",980,1306]